Long-term data confirm safety and efficacy of ustekinumab: The UNITI study evaluated the efficacy and safety of intravenous induction therapy with ustekinumab followed by subcutaneous maintenance therapy and an extension phase in patients with moderately to severely active Crohn’s disease.
